Johnson & Johnson Reports Sustained Efficacy in Vivacity-MG3 Trial and Secures CE Mark for New Surgical Device
Johnson & Johnson (JNJ) reported sustained efficacy of its drug IMAAVY in treating generalized myasthenia gravis, with improved symptom management and safety over time. Additionally, the company secured CE Mark approval for its ETHICON 4000 Stapler, a new surgical device. These developments highlight JNJ's progress in both pharmaceutical and MedTech sectors.
Tickers: $JNJ
Topics: CE Mark clearance clinical trials drug efficacy generalized myasthenia gravis surgical devices